Cancer immunotherapy and vaccine development have significantly improved the fight
against cancers. Despite these advancements, challenges remain, particularly in the clinical …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

Immunosuppressive myeloid cells hinder immunotherapeutic efficacy in tumors, but the
precise mechanisms remain undefined. Here, by performing single-cell RNA sequencing in …

Acute myeloid leukemia (AML) is initiated and sustained by a hierarchy of leukemia stem
cells (LSCs), and elimination of this cell population is required for curative therapies. Here …

Cancer is one of the most common diseases and causes of death worldwide. Since common
treatment approaches do not yield acceptable results in many patients, developing …

Micro/nano‐robots are powerful tools for biomedical applications and are applied in disease
diagnosis, tumor imaging, drug delivery, and targeted therapy. Among the various types of …

The use of colony-stimulating factor-1 receptor (CSF1R) inhibitors has been widely explored
as a strategy for cancer immunotherapy due to their robust depletion of tumor-associated …

Malignant tumors are still one of the most deadly diseases that threaten human life and
health. However, developing new drugs is challenging due to lengthy trials, funding …

Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies in the
world with poor prognosis. Despite the promising applications of immunotherapy, the …

Objectives Our study elucidates the prognostic role of cluster of differentiation (CD) 24
expression in oral squamous cell carcinoma (OSCC) and determines whether targeting …